Bridgebio Pharma, Inc. key statistics and ratios

In fiscal 2025, Bridgebio Pharma, Inc. had an operating margin of -104.2% and a current ratio of 2.77. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Bridgebio Pharma, Inc.: financial ratios, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Gross margin	—	—	95.5%	95.6%	73.7%	98.3%	95.8%	94.3%
Operating margin	−656.4%	<−999%	−827.1%	−659.6%	<−999%	−267.2%	−104.2%	−38.5%
Net margin	−642.5%	<−999%	−806.9%	−619.7%	<−999%	−241.4%	−144.4%	−59.8%
Free-cash-flow margin	−631.7%	<−999%	−733.2%	−546.5%	<−999%	−235.1%	−89.0%	−39.1%
Return on equity	−63.8%	−192.4%	—	—	—	—	—	—
Return on assets	−41.3%	−67.2%	−65.5%	−58.8%	−110.0%	−73.1%	−78.1%	−36.5%
Asset turnover	0.06	0.01	0.08	0.09	0.02	0.30	0.54	0.61
Current ratio	9.42	6.72	6.58	4.52	3.32	4.67	2.77	2.09
Debt to equity	23.3%	162.1%	—	—	—	—	—	—
Interest cover (operating income ÷ interest)	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m
R&D as % of revenue	517.6%	>999%	646.9%	514.5%	>999%	228.2%	90.0%	56.7%
SG&A as % of revenue	232.6%	>999%	275.7%	184.4%	>999%	130.2%	105.8%	75.0%
Capital spending as % of revenue	6.5%	91.1%	19.0%	6.2%	14.0%	0.4%	0.2%	0.1%

US$ thousands unless shown otherwise. Fiscal quarters.

Bridgebio Pharma, Inc.: financial ratios, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Gross margin	64.6%	97.7%	96.7%	94.6%	94.7%	94.9%	93.8%	94.2%
Operating margin	<−999%	−89.5%	−121.4%	−120.3%	−90.5%	−54.5%	−43.9%	−3.3%
Net margin	<−999%	−143.5%	−164.5%	−151.4%	−125.1%	−84.3%	−62.5%	−16.1%
Free-cash-flow margin	<−999%	−170.8%	−73.5%	−91.2%	−36.6%	−101.5%	−29.4%	−12.6%
Current ratio	4.67	4.57	5.19	3.88	2.77	1.52	1.23	2.09
R&D as % of revenue	>999%	95.5%	100.6%	93.5%	75.5%	65.1%	61.3%	40.6%
SG&A as % of revenue	>999%	91.2%	116.8%	114.0%	102.5%	84.3%	76.4%	56.9%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 5 checks passed · September 30, 2026

What it owns · $2.2bn

Short-term assets $2.0bnLonger-term assets $117m

What it owes, and who funded it · $3.8bn

Short-term liabilities $977mLonger-term liabilities $2.8bnShareholders' equity $-1.7bn

Short-term assets cover short-term liabilities $2.0bn of assets due within a year against $977m of liabilities due within a year.
Short-term assets cover long-term liabilities $2.0bn short-term assets against $2.8bn of longer-dated liabilities.
More cash than debt $1.5bn of cash against $2.6bn of debt.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt −$369m of operating cash flow against $2.6bn of debt.
Operating profit covers interest at least five times over Operating income of −$364m against $51m of interest.

From Bridgebio Pharma, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

8 /100

Weak moat

How hard Bridgebio Pharma's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 0 / 20

Net income has been a median -66.7% of total assets over 8 years.
Durability 10 / 20

Operating margin has been a median -434.3%; its worst year was -5931.1%.
Cash conversion 0 / 20

Free cash flow was positive in 0 of 6 years, at a median -366.9% of revenue.
Discipline 0 / 20

The diluted share count rose 41.6% over five years; stock-based pay has been a median 74.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: BBIO vs KNSA BBIO vs BCRX BBIO vs IONS BBIO vs LEGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Bridgebio Pharma, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bridgebio Pharma, Inc.